A Shareholder Lawsuit Stemming From Aphria Could Expose Tilray—Trouble In Cannabis Paradise?

Comments
Loading...

Canadian cannabis giant Tilray, Inc. TLRY, which closed its acquisition of rival Aphria, Inc. (APHA) in 2021, could face a lawsuit brought by former Aphria shareholders.

Background:

In 2021, after months of negotiations, Tilray and Aphria merged creating a company with a combined market cap of $3.3 billion at that time.

The two Canadian cannabis giants had been in talks since December 2020 to create a new enterprise, led by Aphria’s current CEO Irwin Simon.

Under the deal, each Aphria shareholder received 0.8381 of a Tilray share for each Aphria common share held on April 30, 2021.

What Happened?

Apparently, the former shareholders of the company accuse Tilray of misleading investors about some assets it acquired, reported Bloomberg Law.

Recently, a judge in the US District Court for the Southern District of New York ruled that the shareholders can represent a class.

Moreover, Judge George Daniels said that stockholder allegations that they relied on Aphria misrepresentations "are capable of common proof through a fraud-on-the-market theory."

Nevertheless, Seeking Alpha's Quant Rating views Tilray as a hold with strong grades for valuation and growth.

Photo: Courtesy Of Sasun Bughdaryan On Unsplash

 

Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.